At what enterprise value was LIFEBRAIN acquired in 2021?

During the acquisition of LIFEBRAIN by CERBA HEALTHCARE in 2021, the company was valued at an estimated revenue multiple of 5x - 12x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LIFEBRAIN when it was acquired by CERBA HEALTHCARE?

The estimated EV/EBITDA multiple for LIFEBRAIN is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was LIFEBRAIN acquired by CERBA HEALTHCARE?

LIFEBRAIN was acquired by CERBA HEALTHCARE in 2021.

What was the revenue of LIFEBRAIN at the time of the deal?

The revenue of LIFEBRAIN at the time of the deal is estimated to be in the range of 150M - 250M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of LIFEBRAIN during the acquisition?

LIFEBRAIN's EBITDA is estimated to be in the range of 100M - 200M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LIFEBRAIN acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LIFEBRAIN deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.cerbahealthcare.com/fr/communique-de-presse/cerba-healthcare-finalise-lacquisition-de-lifebrain-en-italie

← DATABASE

Home Database Healthcare & PharmaLIFEBRAIN

07/2021

LIFEBRAIN acquired by CERBA HEALTHCARE

ITALY Health Providers / Healthcare Facilities / Labs (Biology) EV 1b - 4b EUR

Context

Cerba HealthCare won a highly competitive auction process managed by Goldman Sachs and JP Morgan to acquire Lifebrain from Investindustrial. The transaction marks Cerba's entry as a major player in the Italian market, significantly expanding its European footprint. The acquisition follows a period of rapid growth for the target, which doubled its profitability between 2019 and 2021, partly driven by a high volume of pandemic-related testing. The deal received backing from Cerba's new majority shareholder, EQT, alongside long-term partners.

Investindustrial had previously taken control of the company during an LBO in 2018.

LIFEBRAIN, which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Lifebrain is Italy's largest provider of clinical laboratory testing services. The group operates a vast network of approximately 360 sites across the country and generates over EUR200 million in revenue. Beyond its core medical diagnostics business, Lifebrain has successfully diversified into environmental and food safety testing markets. Under its previous ownership, the company became a prolific consolidator, completing 70 acquisitions in just three years to achieve its current scale.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Other operations with LIFEBRAIN

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
04/2018	INVESTINDUSTRIAL	LIFEBRAIN	ITALY	Health Providers	Investindustrial acquired a controlling stake in Lifebrain from the investment vehicle lb EK Management. The deal follows a period of intense growth supported by MCI Capital, during which the group established itself as a leading consolidator in the fragmented Italian laboratory market. The acquisition was structured through a Luxembourg vehicle, European Laboratory Services, and aimed to provide the capital and expertise necessary to professionalize the group and accelerate its aggressive acquisition strategy across Italy.

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 150M - 250M EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LIFEBRAIN by CERBA HEALTHCARE are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: cerba healthcare